Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC. Remon J, Hendriks LEL. J Thorac Oncol 2021;16:368-370.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Remon J, Hendriks LEL. Osimertinib Should be the Standard of Care for the Adjuvant Therapy of Stage IB to IIIA EGFR-Mutant NSCLC. J Thorac Oncol 2021;16:368-370.
PMID: 33641720